Definitive Healthcare (NASDAQ:DH) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Definitive Healthcare (NASDAQ:DH) from a hold rating to a buy rating in a research report sent to investors on Sunday morning,Wall Street Zen reports.

Other research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Monday, August 31st. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $1.00 target price on shares of Definitive Healthcare in a report on Wednesday, August 12th. Bank of America restated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a research note on Monday, June 29th. Morgan Stanley lowered their target price on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a report on Tuesday, August 11th. Finally, BTIG Research reiterated a “neutral” rating on shares of Definitive Healthcare in a research report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Definitive Healthcare has an average rating of “Reduce” and an average price target of $1.47.

Definitive Healthcare Price Performance

Shares of NASDAQ DH opened at $1.05 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $112.09 million, a price-to-earnings ratio of -0.66, a price-to-earnings-growth ratio of 12.96 and a beta of 1.40. Definitive Healthcare has a twelve month low of $0.61 and a twelve month high of $4.35. The business has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $0.92.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Monday, August 10th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. The firm had revenue of $55.20 million during the quarter, compared to the consensus estimate of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. As a group, equities research analysts expect that Definitive Healthcare will post 0.06 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

Several hedge funds have recently bought and sold shares of DH. Goldman Sachs Group Inc. boosted its stake in Definitive Healthcare by 564.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Definitive Healthcare in the second quarter valued at approximately $4,247,000. Inspire Investing LLC raised its holdings in shares of Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after buying an additional 583,562 shares during the last quarter. Corient Private Wealth LP acquired a new stake in Definitive Healthcare in the 2nd quarter valued at approximately $378,000. Finally, Millennium Management LLC increased its position in Definitive Healthcare by 230.9% in the 4th quarter. Millennium Management LLC now owns 332,087 shares of the company’s stock valued at $953,000 after acquiring an additional 231,743 shares during the period. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.